The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women

Gynecological Endocrinology

Volumn 23, Issue 4, 2007, Pages 183-185

  Genazzani, Andrea R ^a   Gambacciani, Marco ^a   Simoncini, Tommaso ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONOLOGY; CLINICAL PRACTICE; CORONARY RISK; EDITORIAL; ESTROGEN THERAPY; EVALUATION; HAZARD ASSESSMENT; HUMAN; MENOPAUSAL SYNDROME; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING TEST; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WOMEN'S HEALTH;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RISK FACTORS;

EID: 34248574237     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701385081     Document Type: Editorial

References (23)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-1712.
3. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
4. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
5. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-1477.
6. Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecol Endocrinol 2002;16:255-257.
7. Gambacciani M, Genazzani AR. The missing R. Gynecol Endocrinol 2003;17:91-94.
8. Genazzani AR, Gambacciani M. The sound of an international anti-HRT herald. Maturitas 2003;46:105-106.
9. Genazzani AR, Gambacciani M, Simoncini T. Estrogens and women's health: a scary or a fairy tale? Gynecol Endocrinol 2004;18:175-178.
10. Gambacciani M, Genazzani AR. The Xmas present for women's health: a strike to osteoporosis prevention. Maturitas 2004;48:9-11.
11. Stevenson J, Whitehead M. Hormone replacement therapy. Findings of Women's Health Initiative trial need not alarm users. Br Med J 2002;325:113-114.
12. Schneider HPG. The view of The International Menopause Society on the Women's Health Initiative. Climacteric 2002;5:211-216.
13. Neves-e-Castro M, Samsioe G, Doren M, O Skouby S. Results from WHI and HERS II - implications for women and the prescriber of HRT. Maturitas 2002;42:255-258.
14. Creasman WT, Hoel D, DiSaia PJ. WHI: now that the dust has settled. A commentary. Am J Obstet Gynecol 2003;189:621-626.
15. Speroff L. WHI trial: it's time to be critical! Am J Obstet Gynecol 2003;189:620.
16. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;5:302-310.
17. Shapiro S. Adverse neoplastic and cardiovascular outcomes of HRT. The validity of the evidence. Endocrine 2004;24:203-210.
18. Studd J. 'Up to general practice to pick up the pieces' - what pieces? A response to WHI and MWS. Maturitas 2003;46:95-96.
19. Naftolin F, Schneider HP, Sturdee DW, Birkhauser M, Brincat MP, Gambacciani M, Genazzani AR, Limpaphayom KK, O'Neill S, Palacios S, et al. Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:333-337.
20. Studd J. Second thoughts on the Women's Health Initiative study: the effect of age on the safety of HRT. Climacteric 2004;7:412-414.
21. Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric 2006;9:416-420.
22. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933-941.
23. Genazzani AR, Simoncini T. Timing is everything. Gynecol Endocrinol 2007;23:00-00.